Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
- Address
- lock Available on a paid plan
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego is a leading academic medical center conducting cutting-edge clinical research across multiple therapeutic disciplines. The center specializes in complex hematologic malignancies, autoimmune disorders, and cardiovascular conditions, with particular expertise in innovative biological therapies and advanced treatment protocols.
- Hematologic malignancies including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and lymphomas
- Autoimmune and neuromuscular disorders such as myasthenia gravis, systemic lupus erythematosus, and multiple sclerosis
- Cardiovascular diseases including atrial fibrillation, heart failure, and myocardial injury prevention
- Rare diseases including spinal muscular atrophy, Duchenne muscular dystrophy, and amyloidosis
The center demonstrates exceptional capabilities in conducting Phase 3 trials for novel monoclonal antibodies, CAR T-cell therapies, and targeted biologics. Research efforts emphasize personalized medicine approaches, including minimal residual disease (MRD)-guided treatment strategies and innovative combination therapies. The institution maintains strong expertise in pediatric clinical trials, chronic kidney disease management with advanced therapeutics, and critical limb ischemia interventions, positioning it at the forefront of translational medicine and patient-centered clinical research in Poland.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novartis Pharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) | Novartis Pharma AG | Phase III | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisolone | 2 | Unknown | 2020-07-16 | 2023-05-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.